Drug Trial Radar · NCT06475781
Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Mar 1, 2025
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Foresee Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- QPS Holdings LLC
- First posted
- Jun 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to see if mirivadelgat will work in participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD). It will also learn about the safety of mirivadelgat. The main question it aims to answer is if mirivadelgat will improve pulmonary vascular resistance (PVR). Pulmonary vascular resistance is a way to measure blood flow in the lungs. Researchers will compare mirivadelgat to a placebo (a look-alike capsule that contains no drug) to see if mirivadelgat works to improve the symptoms of PH-ILD. The symptoms of PH-ILD that are being looked at are exercise tolerance, heart function, and general well-being. Participants will: Take mirivadelgat or a placebo once a day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests Receive phone calls every one or two weeks to check on how things are going
Conditions
- Group 3 Pulmonary Hypertension
Interventions
MirivadelgatDrug
Selective aldehyde dehydrogenase 2 (ALDH2) activator
placeboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pulmonary Vascular Resistance (PVR)Time frame: 12 weeks
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
University Clinical Centre of the Republic of Srpska
Banja Luka, Bosnia and Herzegovina · Not yet recruiting
Clinical Center of the University of Sarajevo
Sarajevo, Bosnia and Herzegovina · Not yet recruiting
Acad. G Chapidze Emergency Cardiology Center LLC
Tbilisi, Georgia · Recruiting
JSC Viani - Iv. Bokeria University Hospital
Tbilisi, Georgia · Recruiting
LTD Open Heart - University Hospital
Tbilisi, Georgia · Recruiting
Tbilisi Heart Center LLC
Tbilisi, Georgia · Recruiting
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan · Terminated
MacKay Memorial Hospital
Taipei, Taiwan · Recruiting
Hualien Tzu Chi Hospital
Hualien City, Taiwan, Taiwan · Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan, Taiwan · Terminated
Taichung Veterans General Hospital
Taichung, Taiwan, Taiwan · Recruiting
National Cheng Kung University Hospital
Tainan, Taiwan, Taiwan · Terminated
National Taiwan University Hospital
Taipei, Taiwan, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan, Taiwan · Recruiting
Chang Gung Memorial Hospital - Linkou Branch
Taoyuan City, Taiwan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.